Skip to main content

Healthy Male Volunteers

14
Pipeline Programs
16
Companies
50
Clinical Trials
12 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 23 programs with unclassified modality

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Hanlim Pharm
Hanlim PharmKorea - Seoul
4 programs
4
CelecoxibPhase 1Small Molecule1 trial
HL237 tabletPhase 11 trial
Livasupril Cap.160/2mgPhase 11 trial
micronized fenofibrate 160mgPhase 11 trial
Active Trials
NCT01549743Completed30Est. Jun 2012
NCT04633733Unknown24Est. Jan 2021
NCT02250976Completed41Est. Oct 2014
+1 more trials
Chong Kun Dang Pharmaceutical
3 programs
3
MetforminPhase 11 trial
S-amlodipine 5mg,Telmisartan 80mgPhase 11 trial
Telmisartan 80mg, S-amlodipine 5mgPhase 11 trial
Active Trials
NCT01005160Completed24Est. Feb 2010
NCT01356043Completed24Est. Aug 2011
NCT01356017Completed32Est. Sep 2011
Pfizer
PfizerNEW YORK, NY
2 programs
2
NXL104Phase 12 trials
[14C] PF-07976016Phase 11 trial
Active Trials
NCT01448395Completed6Est. Nov 2011
NCT01290900Completed54Est. May 2011
NCT07015918Completed8Est. Aug 2025
Prevail Therapeutics
1 program
1
DrugPhase 1
Hanmi Pharmaceutical
1 program
1
HGP1607Phase 11 trial
Active Trials
NCT03089112Completed30Est. Jun 2017
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
IV methylnaltrexonePhase 11 trial
Active Trials
NCT01367483Completed6Est. Jun 2005
Orion Pharma
Orion PharmaUK - Reading
1 program
1
ORM-12741Phase 11 trial
Active Trials
NCT00817544Completed6Est. Mar 2009
Orion
OrionUK - Cambridge
1 program
1
ORM-12741Phase 1
UCB Pharma
UCB PharmaBelgium - Brussels
3 programs
LacosamideN/A1 trial
LacosamidePHASE_11 trial
UCB0107PHASE_11 trial
Active Trials
NCT01382017Completed18Est. Aug 2012
NCT03086382Completed24Est. Mar 2017
NCT03464227Completed52Est. Dec 2018
Bristol Myers Squibb
2 programs
BMS-986165PHASE_15 trials
[14C]-BMS-986196PHASE_11 trial
Active Trials
NCT06875960Recruiting35Est. Dec 2026
NCT06979453Recruiting366Est. Aug 2034
NCT06869551Recruiting60Est. Mar 2031
+3 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
DrugPHASE_15 trials
Active Trials
NCT00034606Completed
NCT00089869Completed
NCT00034619Completed
+2 more trials
Eisai
EisaiChina - Liaoning
1 program
E6011PHASE_11 trial
Active Trials
NCT01731275Completed64Est. Aug 2013
Opko Health
Opko HealthMIAMI, FL
1 program
SomatrogonPHASE_11 trial
Active Trials
NCT03810664Completed49Est. Apr 2019
Xenon Pharmaceuticals
1 program
XPF-008PHASE_11 trial
Active Trials
NCT03468725Completed20Est. Jul 2018
PMV Pharma
PMV PharmaPRINCETON, NJ
1 program
[14C]-PC14586PHASE_11 trial
Active Trials
NCT05523687CompletedEst. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Bristol Myers SquibbBMS-986165
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug
Eli Lilly and CompanyDrug

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 12,767 patients across 50 trials

EVA: Evista Alendronate Comparison

Phase 4Completed

Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

Start: Aug 2026Est. completion: Dec 202860 patients
Phase 4Not Yet Recruiting

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

Start: Jun 2026Est. completion: Sep 202814 patients
Phase 4Not Yet Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start: Mar 2026Est. completion: Dec 2032150 patients
Phase 4Recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Start: Feb 2026Est. completion: Oct 2027344 patients
Phase 4Recruiting

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Start: Feb 2026Est. completion: Dec 202635 patients
Phase 4Recruiting

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Start: Feb 2026Est. completion: Feb 202860 patients
Phase 4Not Yet Recruiting

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Start: Aug 2025Est. completion: Apr 202725 patients
Phase 4Recruiting

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Start: Jun 2025Est. completion: Sep 2026233 patients
Phase 4Active Not Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Start: May 2025Est. completion: Dec 2032279 patients
Phase 4Recruiting

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Start: May 2025Est. completion: Dec 2032787 patients
Phase 4Recruiting

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Start: Mar 2025Est. completion: May 2028200 patients
Phase 4Recruiting

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Start: Mar 2025Est. completion: Nov 2027200 patients
Phase 4Recruiting

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Start: Nov 2024Est. completion: May 2037352 patients
Phase 4Recruiting

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

Start: Oct 2024Est. completion: Apr 2026166 patients
Phase 4Completed

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Start: Apr 2024Est. completion: Jul 202715 patients
Phase 4Active Not Recruiting

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Start: Apr 2024Est. completion: Sep 2025150 patients
Phase 4Completed

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Start: Jan 2024Est. completion: May 2026120 patients
Phase 4Recruiting

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

Start: Sep 2023Est. completion: May 20240
Phase 4Withdrawn

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Start: Jun 2023Est. completion: Sep 2024250 patients
Phase 4Completed

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Start: Mar 2023Est. completion: Oct 2023152 patients
Phase 4Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Start: Dec 2022Est. completion: Jan 2024212 patients
Phase 4Completed

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Start: Nov 2022Est. completion: Aug 2024282 patients
Phase 4Completed

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Start: Aug 2022Est. completion: Nov 2027780 patients
Phase 4Active Not Recruiting

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Start: Jun 2022Est. completion: Dec 202420 patients
Phase 4Unknown

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

Start: Apr 2022Est. completion: Apr 2029300 patients
Phase 4Recruiting

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Start: Mar 2022Est. completion: Nov 202660 patients
Phase 4Active Not Recruiting

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Start: Dec 2021Est. completion: May 2023580 patients
Phase 4Completed

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

Start: Aug 2021Est. completion: Jun 20220
Phase 4Withdrawn

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Start: Feb 2021Est. completion: Jan 2023200 patients
Phase 4Completed

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

Start: Jan 2021Est. completion: Apr 2021139 patients
Phase 4Terminated

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Start: Oct 2020Est. completion: Mar 202165 patients
Phase 4Completed

Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia

Start: Jul 2020Est. completion: Jan 202326 patients
Phase 4Completed

Taltz in Combination With Enstilar for Psoriasis

Start: Apr 2020Est. completion: Mar 202125 patients
Phase 4Recruiting

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Start: Dec 2019Est. completion: Jul 2021304 patients
Phase 4Completed

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Start: Sep 2019Est. completion: Mar 20230
Phase 4Withdrawn

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Start: Aug 2019Est. completion: Aug 20204 patients
Phase 4Terminated

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Start: Jul 2019Est. completion: Jul 202012 patients
Phase 4Completed

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Start: Apr 2019Est. completion: May 20252,663 patients
Phase 4Completed

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Start: Nov 2018Est. completion: Jan 20201,027 patients
Phase 4Completed

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Start: Oct 2018Est. completion: Apr 2019312 patients
Phase 4Completed

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Start: Oct 2017Est. completion: Feb 201812 patients
Phase 4Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Start: Aug 2016Est. completion: Jun 2018159 patients
Phase 4Completed

Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

Start: Dec 2015Est. completion: Jun 202086 patients
Phase 4Completed

A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)

Start: Apr 2015Est. completion: May 2017304 patients
Phase 4Completed

A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).

Start: Apr 2015Est. completion: Feb 2016171 patients
Phase 4Completed

A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction

Start: Oct 2014Est. completion: May 2017635 patients
Phase 4Completed

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Start: Feb 2013Est. completion: May 2014325 patients
Phase 4Completed

Comparison of Insulin Mix25 Versus Mix50

Start: Jan 2013Est. completion: Aug 2014403 patients
Phase 4Completed

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

Start: Jan 2013Est. completion: Jun 201469 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

12 actively recruiting trials targeting 12,767 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.